Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

SIRT1: A Therapeutic Target for Osteoporosis?

  |  

New research has found the sirtuin family of proteins may be a positive regulator of bone mass. In the study, pharmacological activation of SIRT1 in mice resulted in increased bone mass, suggesting the pharmacological activation of SIRT1 may protect against osteoporosis…

Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More

Angus Worthing, MD, FACP, FACR   |  

Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….

Year in Review: Expert Covers 2017’s Key Clinical Findings

  |  

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

Deena Beasley  |  

(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…

Biosimilars Great Debate: To Switch or Not?

  |  

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Lower Medicaid Fees Linked to Scarcer Primary Care Appointments

Cheryl Platzman Weinstock  |  

(Reuters Health)—When the fees paid to healthcare providers by Medicaid go up, appointments with primary care doctors suddenly become more available to Medicaid beneficiaries – and the opposite happens when fees go down, according to a recent U.S. study. Researchers found that, overall, every $10 change up or down in the Medicaid fees paid to…